This is an old revision of this page, as edited by DePiep(talk | contribs) at 16:16, 2 April 2016(Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 16:16, 2 April 2016 by DePiep(talk | contribs)(Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script))
EiPT is short for N-ethyl-N-isopropyl-tryptamine. The full chemical name of this structure is N-ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-2-amine. EiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines. EiPT is closely related to the compounds diethyltryptamine (DET) and DIPT.
Dosage
In his book TiHKAL, Alexander Shulgin lists a dosage for EiPT as being 24-40 mg taken orally.
Effects
Very little is known about the psychopharmacological properties of EiPT, but reports suggest it produces psychedelic effects that can last 4-6 hours. According to Shulgin, this compound tends to produce nausea, dysphoria, and other unpleasant side-effects. It also lacks the hallucinatory and visual properties usually associated with psychedelic drugs.
Dangers
There have been no reported deaths or hospitalizations from EiPT, but its safety profile is unknown.
Legality
EiPT is unscheduled and uncontrolled in the United States, but possession and sales of EiPT could be prosecuted under the Federal Analog Act because of its structural similarities to DET.
